Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Cameron Dorey who wrote (2340)	2/29/2000 6:05:00 PM
From: out_of_the_loop	Read Replies (1) \| Respond to of 5582

I think his point is that the announcement mentions the type of research that was to be done and when it was supposed to be completed. Some people misunderstood that the recent study by Dr. Hirt to be those studies mentioned in the old press release, but that is not at all the case. Dr. Hirt independently wanted to verify and did verify the original company studies using a symptomatic patient population. The Zicam studies that were mentioned in the press releases last year were done at major universities and will look at prevention. Since they were scheduled to be completed by October, 1999, Streetwalker is suggesting that they are most likely under review.

To: Cameron Dorey who wrote (2340)	2/29/2000 6:17:00 PM
From: DanZ	Read Replies (2) \| Respond to of 5582

Cameron, The fact that the article is over seven months old is exactly the point. The clinical study was supposed to have been finished by October 99. Even allowing for a month of normal delays, the only possible conclusion is that the results have been submitted for publication. We are still waiting for the results of the three studies discussed in the press release, i.e., "confirming ZICAM(TM)'s ability to significantly reduce the duration of the common cold; exploring ZICAM(TM)'s ability to act as a preventive measure against the common cold and its symptoms; and testing ZICAM(TM)'s ability to relieve symptoms caused by allergic reactions to common airborne allergens." Gum Tech doesn't have any control over a journal's schedule, and I think that investors will wake up one day to news that one or more of these studies will be published. GUMM could easily react the same way that VPHM did when they got so much publicity a few weeks ago. We already have two positive clinical results, and Gum Tech would have a duty to tell shareholders if either of the other three studies came back negative. Since they haven't done that, I think it's reasonable to speculate that the results ARE positive and HAVE been submitted for publication. PS to hank: You need to look up the definition of "about". The difference between a 63% gain and a 70% gain on a $22 stock is only about 3/4 of a point. As of the Feb 26 status, GUMM was up exactly 70%. I'm not sure how you expect people to take you seriously when you act like such a close minded, immature brat.

To: Cameron Dorey who wrote (2340)	3/2/2000 1:00:00 AM
From: Street Walker	Respond to of 5582

The 7 month old story is a prelude of things to come. The art of investing in a biotech stock is getting to know it really well by old news. News paints a picture for what their vision is. For example, if a company announced they are fast track FDA 9 months ago, that means the FDA has only 3 months left to make a decision. A by passer reading the old news would say, that news is 9 months old and insignificant. Someone doing due dilligence would see an announcement is pending. What do you get from reading the old news I posted? Earnings will be blow out. Expecting sometime mid April. One year ago, KIDE was in the same position as GUMM. Signs of growth and huge short position relative to float. After earnings came out again, KIDE rose super fast, declared a split and then rose again after the split and then split again all within a couple of months. Some of us GUMMer's invested in KIDE (Howard, Bo, Eric and I) and made out well. We'll do better with GUMM. Buy and hold investment strategy with no price targets. Regards, S.W.